Almac supports ATMP launches with expanded European facility

The CDMO has expanded its ultra-low temperature commercial packaging, labelling and distribution solutions facility in Ireland
In line with the expected growth of the Advanced Therapy Medicinal Products (ATMP) market, Almac Pharma Services has expanded its ultra-low temperature commercial packaging, labelling and distribution solutions from its European Centre of Excellence in Ireland.
The company's bespoke Just-in-Time labelling, packaging and serialisation at ultra-low temperatures (-20 °C to -80 °C) has been enhanced to meet the specific requirements of both the client and the product.
Given the nature of ATMPs, it is imperative Qualified Person (QP) release does not become a bottleneck point. Therefore, the company's expansion also includes a bespoke end-to-end consultancy service with a dedicated team of fully qualified and licenced QPs to provide advice on every aspect of ATMP launch.
The CDMO, which is part of the Almac Group and was one of the first European CDMOs to support gene therapy product launches, says its expanded solutions enable processing and QP release of tailored treatment in as little as 20 hours.
Almac's Centre of Excellence, located in Ireland, offers an expansive storage facility with specialist suites and freezer capacity to enable inventory stock of crucial product supply ready for rapid distribution when required.
Mark English, VP Packaging & Logistics for Almac Pharma Services said: "We are cognisant that we implement robust and timely processes, underpinned by Quality Risk Management and designed to protect the integrity of the product whilst ensuring it gets to the patient on time."
Almac says it currently provides solutions for more than 30% of EU approved/pre-registration ATMPs, having processed and QP released in excess of 600 batches to date.
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance